Integra Lifesciences Holdings (IART) Gross Profit (2009 - 2026)

Integra Lifesciences Holdings has disclosed Gross Profit across 18 years of filings, most recently posting $219.7 million for Q2 2026.

• In Q2 2026, Gross Profit rose 4.97% year-over-year to $219.7 million; the TTM figure through Jun 2026 stood at $864.6 million (up 1.35% YoY), while the FY2025 annual figure was $831.6 million, down 5.72% from the prior year.
• Gross Profit came in at $219.7 million for Q2 2026 at Integra Lifesciences Holdings, up from $217.0 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $250.1 million in Q4 2022 to a low of $194.4 million in Q1 2025.
• Average Gross Profit over 5 years is $222.5 million, with a median of $220.3 million recorded in 2025.
• Year-over-year, Gross Profit dropped 16.99% in 2023 and climbed 11.6% in 2026.
• Over 5 years, Gross Profit stood at $250.1 million in 2022, then dropped by 9.43% to $226.5 million in 2023, then rose by 9.97% to $249.1 million in 2024, then retreated by 11.32% to $220.9 million in 2025, then dropped by 0.51% to $219.7 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $219.7 million in Q2 2026, $217.0 million in Q1 2026, and $220.9 million in Q4 2025.